Abstracts tagged "pregnancy"

Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0440 • ACR Convergence 2024
Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Jessica English¹, Bethany Wolf² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Women with systemic lupus erythematosus (SLE) have increased rates of pre-term birth, small for gestational age babies, and pre-eclampsia compared to women without a…
Abstract Number: 0807 • ACR Convergence 2024
Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events
Rashmi Dhital¹, Rebecca Baer², Kenneth Kalunian³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, ³University of California San Diego, La Jolla, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…
Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Melissa Fazzari¹, Jane Salmon², Marta Guerra², Nathalie Costedoat-Chalumeau³, Veronique LE GUERN⁴, Gaëlle Guettrot-Imbert⁴, Marta Mosca⁵, Dina Zucchi⁶, Chiara Tani⁷, Rebecca Fischer-Betz⁸, Isabell Haase⁹, Anna Broder¹⁰, Navneet Kaur¹¹, Jill Buyon¹², Brooke Cohen¹², Diane Kamen¹³, Jessica English¹⁴, Anna Arar¹³ and Mimi Kim¹⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Inserm DR Paris 5, Paris, France, ⁴Cochin hospital, Paris, France, ⁵University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Italy, ⁸Uniklinik Düsseldorf, Düsseldorf, Germany, ⁹Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹⁰Hackensack Network, Hackensack, NJ, ¹¹Touro University Medical Group, Sacramento, CA, ¹²NYU Grossman School of Medicine, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Medical University of South Carolina, Johns Island, SC, ¹⁵Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
Abstract Number: 0417 • ACR Convergence 2024
Contraception in Community Rheumatology Practices
Megan Clowse¹, Julie Chiesa², Pamela Freeman³, Bansari Gujar⁴, Kelley Jones⁵, Richard Jones⁶, Ann Marslett⁷, Amanda Snyderman⁵ and Leah Zulig⁸, ¹Duke University, Chapel Hill, NC, ²InfoDirectors, Durham, NC, ³Rheumatology Associates of Central Florida, Orlando, FL, ⁴Rheumatology Associates of Baltimore, Towson, MD, ⁵Duke University School of Medicine, Durham, ⁶Clinic for Rheumatic Diseases, Northport, AL, ⁷Rheumatology Associates of Baltimore, Baltimore, MD, ⁸Duke University School of Medicine, Durham, NC
Background/Purpose: Most prior studies of contraception in women with rheumatic disease focused on academic centers. In this study of non-academic rheumatology practices, we sought to…
Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Dahima Cintron¹, Jennifer Rogers², Rebecca Sadun¹, Mithu Maheswaranathan³, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…
Abstract Number: 0808 • ACR Convergence 2024
Confirmation of Second Trimester Trophoblast Transport of Maternal Anti-SSA/Ro52 and 60kD Autoantibodies in Cardiac Neonatal Lupus: Implications for FcRn Blockade
Nicola Fraser¹, Mala Masson², Robert Clancy³, Philip Carlucci⁴, Peter Izmirly⁵, Nalani Sachan⁶, Justin Brandt¹, Kristen Thomas¹, Melanie Fox⁷, Colin Phoon¹, Achiau Ludomirsky¹, Ranjini Srinivasan¹, Garrett Lam⁸, Bettina Cuneo⁹ and Jill Buyon¹⁰, ¹NYU Langone Health, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³Columbia University Medical Center, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Renown Health, Reno, NV, ⁸Intermountain Health, Provo, UT, ⁹University of Arizona College of Medicine, Tucson, AZ, ¹⁰New York University Grossman School of Medicine, New York, NY
Background/Purpose: The nearly invariant finding of anti-SSA/Ro52/60kD autoantibodies in pregnancies complicated by cardiac neonatal lupus (cardiac-NL), which manifests as fetal atrioventricular block and endocardial fibroelastosis…
Abstract Number: 2591 • ACR Convergence 2024
Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study
Yasmine Shakur¹, Charmayne M. Dunlop-Thomas², S. Sam Lim¹ and Subasri Narasimhan¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition that primarily affects women of childbearing age, with many patients being diagnosed during puberty. Contraception…
Abstract Number: 0418 • ACR Convergence 2024
Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Megan Clowse¹, Puneet Bajaj², Bonnie Bermas², Julie Chiesa³, Kathryn Dao⁴, Pamela Freeman⁵, Bansari Gujar⁶, Brittany Hill⁷, Kelley Jones⁸, Richard Jones⁹, Ann Marslett¹⁰, Brooke Mills¹¹, James Roberts², Amanda Snyderman⁸ and Leah Zulig¹², ¹Duke University, Chapel Hill, NC, ²UT Southwestern Medical Center, Dallas, TX, ³InfoDirectors, Durham, NC, ⁴Rheum101, Rockville, MD, ⁵Rheumatology Associates of Central Florida, Orlando, FL, ⁶Rheumatology Associates of Baltimore, Towson, MD, ⁷Clinic for Rheumatic Disease, Tuscaloosa, AL, ⁸Duke University School of Medicine, Durham, ⁹Clinic for Rheumatic Diseases, Northport, AL, ¹⁰Rheumatology Associates of Baltimore, Baltimore, MD, ¹¹UT Southwestern Medical Center, Fort Worth, TX, ¹²Duke University School of Medicine, Durham, NC
Background/Purpose: Prior studies of RISE Registry found 9-11% of women of reproductive age with contraception documentation. We sought to identify and assess methods to increase contraception documentation…
Abstract Number: 0442 • ACR Convergence 2024
Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Anam Nazir¹, Joshua Reed², Khalid Alghamdi² and Catherine Ivory¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…
Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Megan Clowse¹, Kateena Addae-Konadu², Jerome Federspiel³, Jennifer Gilner², Andra James², Eugene Kovalik², Anika Lucas³, Laura Neil², Catherine Sims⁴, Amanda Snyderman², Samir Soneji² and Amanda Eudy⁵, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…
Abstract Number: 0422 • ACR Convergence 2024
Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Sabrina Hamroun¹, Grégoire Martin De Frémont², Nathalie Costedoat-chalumeau³, Marion couderc⁴, René-Marc Flipo⁵, Jérémie Sellam⁶, Christophe Richez⁷, Rakiba Belkhir⁸, Laure Gossec⁹, Hubert Marotte¹⁰, Emmanuelle Dernis¹¹, Aline Frazier¹², Elisabeth Gervais¹³, Cedric Lukas¹⁴, Valerie Devauchelle¹⁵, Alban Deroux¹⁶, Véronique Le Guern¹⁷, Gaëlle Guettrot-Imbert¹⁸, Nathalie Lelong¹⁹, Camille Le Ray¹⁹, Raphaele Seror²⁰ and Anna Molto²¹, and ENP 2021 and GR2 Study Groups, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, ³University Paris Cité, Paris, France, ⁴CHU de Clermont-Ferrand, Clermont-Ferrand, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France, ⁶Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ⁷Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ⁹Sorbonne Université, Paris, France, ¹⁰Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹¹CH LE MANS, LE MANS, Pays de la Loire, France, ¹²Lariboisière University Hospital, Paris, France, ¹³University hospital, Poitiers, France, ¹⁴Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁵UBO, Brest, France, ¹⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁷APHP, Hôpital Cochin, Paris, ¹⁸Cochin Hospital, Paris, France, ¹⁹University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, ²⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²¹Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with SpA is suggested in the literature in several countries,…
Abstract Number: 0443 • ACR Convergence 2024
Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Hiromi Shimada¹, Rina Mino², taichi miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Mao Mizusaki², Hayamasa yamaguchi², Naoto Manabe², Shusaku Nakashima¹ and Hiroaki Dobashi¹, ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan
Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…
Abstract Number: 0810 • ACR Convergence 2024
Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation
Sabrina Hamroun¹, Andrea Pluma², Linda Rüegg³, Malte Kramer⁴, Yvette Meissner⁵, Axel Finckh⁶ and Frauke Foerger⁷, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Inselspital, Bern University Hospital, Bern, Switzerland, ⁴German Rheumatism Research Centre Berlin, Epidemiology and Health Services Research, Berlin, Germany, ⁵Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷University hospital Bern /Inselspital Bern, Bern, Switzerland
Background/Purpose: The management of women with musculoskeletal disorders during pregnancy and lactation presents many challenges. Since the first EULAR points to consider for the use…
Abstract Number: 0423 • ACR Convergence 2024
Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Sabrina Hamroun¹, Grégoire Martin De Frémont², Nathalie Costedoat-chalumeau³, Marion couderc⁴, René-Marc Flipo⁵, Laure Gossec⁶, Christophe Richez⁷, Rakiba Belkhir⁸, Aline Frazier⁹, Valerie Devauchelle¹⁰, Hubert Marotte¹¹, Jérémie Sellam¹², Elisabeth Gervais¹³, Alban Deroux¹⁴, Cedric Lukas¹⁵, Emmanuelle Dernis¹⁶, Emmanuel Chatelus¹⁷, Véronique Le Guern¹⁸, Gaëlle Guettrot-Imbert¹⁹, Nathalie Lelong²⁰, Camille Le Ray²⁰, Raphaele Seror²¹ and Anna Molto²², and ENP 2021 and GR2 Study Groups, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, ³University Paris Cité, Paris, France, ⁴CHU de Clermont-Ferrand, Clermont-Ferrand, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France, ⁶Sorbonne Université, Paris, France, ⁷Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ⁹Lariboisière University Hospital, Paris, France, ¹⁰UBO, Brest, France, ¹¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹²Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ¹³University hospital, Poitiers, France, ¹⁴Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁵Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁶CH LE MANS, LE MANS, Pays de la Loire, France, ¹⁷Rheumatology department strasbourg, Strasbourg, France, ¹⁸APHP, Hôpital Cochin, Paris, ¹⁹Cochin Hospital, Paris, France, ²⁰University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, ²¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²²Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with RA is suggested in the literature in several…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].